Canadian sensor manufacturer Opsens has announced that it will be acquired by healthcare company Haemonetics in a deal worth 345 million Canadian dollars ($253.9 million). This move follows a thorough strategic review.
Under the terms of the agreement, Haemonetics, based in Boston, Massachusetts, and its wholly owned subsidiary, will purchase Opsens at C$2.90 per share in cash. This offer represents a significant 50% premium to Opsens’ closing price on Friday, when its stock closed at C$1.93 per share.
Although Opsens’ stock has experienced a modest 2.7% increase this year, it has still faced a decline of 24% over the last 12 months.
Opsens anticipates that the combination of its fiber optic sensors with Haemonetics’ hospital-based products will contribute to improved patient care. The company believes that its expertise in research and development, as well as production, will complement Haemonetics’ commercial and manufacturing capabilities and enable wider adoption of their joint product offerings globally.
Alan Milinazzo, the Executive Chairman of Opsens, has affirmed that this acquisition is in the best interests of the company and its shareholders following a comprehensive strategic review.
The transaction is expected to be completed by the end of January 2024.